Researchers have identified a potential new pathway by which gut bacteria may enter the brain, providing fresh insight into the gut-brain axis and its possible role in neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease. The study, published in PLOS Biology, found that a short-term high-fat diet disrupted the intestinal barrier in mice, allowing…
Category: Parkinson’s Disease
Eye movement biomarker may improve measurement of Parkinson’s disease progression
A novel eye movement biomarker has shown greater sensitivity than the current clinical gold standard for measuring Parkinson’s disease progression, according to a multicentre study that could help improve the evaluation of disease-modifying therapies in clinical trials. Published in Pharmaceutical Medicine, the study found that NeuraLight’s digital biomarker, based on eye movement analysis, detected measurable…
Study finds little to no cortical Lewy pathology in Parkinson’s patients undergoing deep brain stimulation
Researchers at the Icahn School of Medicine at Mount Sinai have reported findings that challenge long-held assumptions about how Parkinson’s disease progresses. In a study of living patients undergoing deep brain stimulation (DBS), investigators found little to no evidence of cortical Lewy pathology in the prefrontal cortex, despite many participants having lived with clinically advanced…
First view of alpha-synuclein pathology in the living brain
Researchers have reported the first successful visualisation of pathological alpha-synuclein aggregates in the living human brain using a novel positron emission tomography (PET) tracer, a development that could transform the diagnosis and monitoring of Parkinson’s disease and related neurodegenerative disorders. The study, published in Science Translational Medicine, describes the development and validation of [11C]MODAG-005, a…
Women with Parkinson’s may have more Alzheimer’s-related brain changes than men, study suggests
Women with Parkinson’s disease may be more likely than men to show Alzheimer’s-related changes in the brain, according to research presented at the European Academy of Neurology Congress 2026. The study, led by researchers at Mayo Clinic Arizona, examined 230 autopsy-confirmed cases of Parkinson’s disease from the Arizona Study of Aging and Neurodegenerative Disorders and…
New study reveals different drivers behind rising numbers of Parkinson’s, multiple sclerosis and motor neuron disease
The growing number of people living with Parkinson’s disease (PD), multiple sclerosis (MS) and motor neuron disease (MND) is being driven by different underlying factors, according to new research due to be presented at the European Academy of Neurology (EAN) Congress 2026 and published in Neurology [1,2]. Researchers from France and Sweden analysed nationwide health…
Cure Parkinson’s expands its Research Committee and welcomes new interns
Cure Parkinson’s has announced a significant expansion of its Research Committee, bringing in new members and interns to broaden the expertise guiding the charity’s growing research portfolio. The move reflects the organisation’s commitment to ensuring its funding decisions are informed by a wide range of scientific, clinical and patient perspectives as it works towards disease-modifying…
NeuraLight completes international multicentre Parkinson’s clinical trial
NeuraLight has announced the completion of PALOMA, an international multicentre clinical trial evaluating eye movement based biomarkers as a tool for monitoring disease progression in Parkinson’s disease. The 12-month longitudinal study followed around 300 participants across clinical sites in the US and Europe, making it one of the largest studies to date examining oculometric measures…
Cure Parkinson’s opens new funding call for up to £300k
Cure Parkinson’s International Linked Clinical Trials (iLCT) Pipeline Research Acceleration Programme is welcoming applications to investigate secukinumab in an alpha-synuclein model of Parkinson’s. Each year, a committee of over 20 world-leading Parkinson’s experts meet to evaluate, rank, and prioritise potentially disease-modifying drugs for Parkinson’s as part of their iLCT programme. The goal of this initiative…
Bial reports major progress in phase 2b trial for GBA1-associated Parkinson’s disease
Bial has announced a key operational milestone in its ongoing phase 2b ACTIVATE study evaluating BIA 28-6156 in patients with Parkinson’s disease associated with mutations in the GBA1 gene. The company confirmed that 75% of enrolled patients have now completed the double-blind treatment period through week 78. The ACTIVATE study is assessing the efficacy, safety,…
